Results 161 to 170 of about 2,190 (195)

Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter

Journal of Cataract and Refractive Surgery, 2011
To evaluate the effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter under light and dark luminance conditions.Ophthalmology Department, Tel Aviv Medical Center, Tel Aviv, Israel.Case series.The pupil diameter was measured with a Colvard pupillometer in eyes of healthy volunteers under light (5.0 candelas [cd]/m(2)) and dark (0.0 ...
Gabi, Shemesh, Elad, Moisseiev, Moshe, Lazar, Anat, Kesler   +3 more
openaire   +2 more sources

Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate

Current Drug Delivery, 2010
Micro and nanoparticulate carriers have been in focus in ophthalmic drug delivery with the objective of improving bioavailability, drug targeting and reducing pulse entry of the drug in ocular cul de sac. Polymeric nanoparticles for ocular purpose have potential in reducing the pulse entry and frequency of dosing, thus improving patient compliance.
Kavita H, Singh, Ujwala A, Shinde
openaire   +2 more sources

Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size

Journal of Cataract and Refractive Surgery, 2004
To evaluate the effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size under scotopic and photopic luminance conditions in persons considering laser refractive surgery.Ophthalmic Health Center, Tel Aviv, Israel.The pupil size was measured in 36 eyes of 36 participants under scotopic and photopic conditions using the Colvard pupillometer (
Anat, Kesler, Gabi, Shemesh, Levi, Rothkoff, Moshe, Lazar   +3 more
openaire   +2 more sources

Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use

Cornea, 2017
Purpose: The primary side effects associated with 0.1% brimonidine tartrate (BT) ophthalmic solution with sodium chlorite are allergic conjunctivitis, blepharitis, and conjunctival hyperemia. However, cornea-related side effects are rare.
Yuko, Maruyama, Yoko, Ikeda, Norihiko, Yokoi, Kazuhiko, Mori, Hiroaki, Kato, Morio, Ueno, Shigeru, Kinoshita, Chie, Sotozono   +7 more
openaire   +2 more sources

Vitreous and Aqueous Concentrations of Brimonidine Following Topical Application of Brimonidine Tartrate 0.1% Ophthalmic Solution in Humans

Journal of Ocular Pharmacology and Therapeutics, 2015
To determine the vitreous and aqueous concentrations of brimonidine after topical application of the ophthalmic solution 0.1%.The prospective observational case series included patients with an idiopathic epiretinal membrane or macular hole who were scheduled for a pars plana vitrectomy.
Yoshihiro, Takamura, Takeshi, Tomomatsu, Takehiro, Matsumura, Yuji, Takihara, Seiko, Kozai, Shogo, Arimura, Satoshi, Yokota, Masaru, Inatani   +7 more
openaire   +2 more sources

Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes

Journal of Cataract and Refractive Surgery, 2004
To evaluate the effect of brimonidine tartrate 0.15% ophthalmic solution (Alphagan P) on pupil diameter in eyes of healthy adults under different luminance conditions.Center for Refractive Surgery, Ophthalmology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA.Using a Colvard pupillometer, the pupil diameter was ...
John E, Thordsen, Kraig S, Bower, Brent B, Warren, Richard, Stutzman   +3 more
openaire   +2 more sources

Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane.

Die Pharmazie, 2011
Various efforts have been made to improve the bioavailability and to prolong the residence time of eye drops. Drug loaded polymeric nanoparticles offer several favorable biological properties. Thus, brimonidine tartrate (BT) loaded chitosan (CS) nanoparticles were prepared by inducing the ionic gelation upon addition of sodium tripolyphosphate (TPP ...
Shinde, U. A., Singh, K. H.
openaire   +2 more sources

Brimonidine tartrate: a one-month dose response study.

Ophthalmology, 1997
Brimonidine tartrate is a relatively selective alpha2-agonist that effectively reduces mean intraocular pressure (IOP) and the incidence of IOP spikes after laser trabeculoplasty. The authors were interested in evaluating the dose response of brimonidine when applied topically for a longer duration in patients with elevated IOPs.The authors conducted a
R J, Derick, A L, Robin, T R, Walters, H S, Barnebey, N, Choplin, J, Schuman, E P, Kelley, K, Chen, J F, Stoecker   +8 more
openaire   +1 more source

Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea

Expert Review of Clinical Pharmacology, 2014
Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The goal of this article is to discuss
Lana X, Tong, Angela Yen, Moore
openaire   +2 more sources

Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats

Veterinary Anaesthesia and Analgesia, 2017
To determine the effects of brimonidine tartrate ophthalmic solution on sedation, heart rate (HR), respiratory frequency (fR), rectal temperature (RT) and noninvasive mean arterial pressure (MAP) in healthy cats.Randomized, blinded crossover study, with 1 week washout between treatments.Six healthy purpose-bred cats.Brimonidine tartrate ophthalmic ...
Niwako, Ogata, Teppei, Kanda, Mizuki, Kawahata, Takayasu, Ichikawa, Yuki, Matsumoto, Waka, Morimitsu, Yukiko, Nishino, Takamasa, Itoi, Kayo, Furumoto   +8 more
openaire   +2 more sources